Allergan pharmaceuticals research
Pro Research Analysisby 
Searched over 200M research papers
Allergan Pharmaceuticals Research and Development Focus
Core Pharmaceutical Competencies: Retinoids, Ocular Hypotensives, and Anti-Inflammatory Agents
Allergan has established itself as a leader in several pharmaceutical technology areas. Patent analysis shows that Allergan’s main strengths are in compounds with retinoid-like activity, ocular hypotensive agents, and furanones as anti-inflammatory agents. The company has developed many inventions in these areas, with a particular focus on retinoids and ocular hypotensives, which are closely related and build upon each other to advance treatment options, especially in eye care and inflammation management .
Innovation in Eye Care, Neuromodulation, and Skin Care
Allergan is recognized globally for its innovative products in eye care, neuromodulation (such as Botox), and skin care. The company designs its clinical trials to scientifically assess the benefits, risks, and value of both current and future products, ensuring a strong pipeline in specialty pharmaceutical markets . This commitment to innovation is supported by ongoing research and development efforts, which have continued robustly even after major corporate changes, such as the acquisition by Actavis .
Research Collaborations and Clinical Support
Allergan collaborates extensively with clinicians and researchers worldwide, providing research grants and support for studies in ophthalmology and other therapeutic areas. Many leading experts in the field have received research funding, consultancy fees, or honoraria from Allergan, highlighting the company’s active role in supporting clinical research and advancing new treatments .
Advancements in Migraine Diagnosis and Management
Allergan has also contributed to the development of tools for better diagnosis and management of chronic migraine. A claims-based algorithm, supported by Allergan, has shown promise in identifying patients with undiagnosed chronic migraine, potentially improving care for a large population that often goes unrecognized in clinical settings .
Research in Inflammatory and Metabolic Diseases
Allergan is involved in the development of new therapies for inflammatory and metabolic diseases, such as nonalcoholic steatohepatitis (NASH). For example, the company has supported research on cenicriviroc, a CCR2/CCR5 antagonist, which has shown positive effects on inflammatory cytokines and metabolic parameters in adults with NASH, suggesting a therapeutic impact on inflammation and insulin resistance .
Support for Dermatologic and Aesthetic Research
Allergan also sponsors research and provides editorial support in dermatology and aesthetic medicine, furthering advancements in treatments for cosmetic and reconstructive purposes. The company’s involvement ensures that new findings and innovations are disseminated to the medical community, supporting evidence-based practice in these fields .
Conclusion
Allergan’s pharmaceutical research spans a wide range of therapeutic areas, with core strengths in eye care, neuromodulation, skin care, and anti-inflammatory agents. The company’s commitment to innovation is evident in its robust R&D programs, support for clinical research, and development of new diagnostic and therapeutic tools. Through collaborations and ongoing investment in research, Allergan continues to play a significant role in advancing specialty pharmaceuticals and improving patient care across multiple domains Gillette2014Mogee1998Maltman2012+4 MORE.
Sources and full results
Most relevant research papers on this topic